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Tissue-infiltrating immune cells as prognostic markers in oral
squamous cell carcinoma: a systematic review and meta-
analysis
Elin Hadler-Olsen1,2,3 and Anna Maria Wirsing1
BACKGROUND: Various immune cells have been suggested as prognostic markers for cancer patients. In this article, we present a
systematic review and meta-analysis of studies assessing the prognostic value of tissue-infiltrating immune cells in oral cancer and
discuss the reporting quality of these studies.
METHODS: We performed a systematic literature search and included studies using immunohistochemistry and survival analysis to
assess the prognostic value of tumour-infiltrating T cells, B cells, macrophages, dendritic cells, mast cells and natural killer cells in
oral cancer. We performed meta-analysis of studies providing necessary statistical data and investigated the studies’ adherence to
the REporting recommendations for tumour MARKer prognostic studies (REMARK) guidelines.
RESULTS: Of the 1960 articles identified, 33 were eligible for this systematic review and 8 were included in the meta-analysis.
CD163+M2 macrophages and CD57+ natural killer cells were the most promising predictors of survival in oral cancer patients.
Many studies lacked important information on their design and conduct.
CONCLUSION: Deficiencies in the reporting of study design and conduct make it difficult to draw reliable conclusions about the
suggested markers. The prognostic value of CD163+M2 macrophages and CD57+ natural killer cells should be validated in large,
standardised studies.
British Journal of Cancer (2019) 120:714–727; https://doi.org/10.1038/s41416-019-0409-6
BACKGROUND
Squamous cell carcino mas (SCC) account for the vast majority of
oral (O) cancer.1 Surgery, often accompanied by radiotherapy, is
the standard treatment for these tumours.2 The radiation causes
severe, chronic side effects including xerostomia and problems
with speech, oral intake and dental health, which makes it
important to avoid overtreatment.3 Currently, the most reliable
prognostic factor for OSCC patients is the TNM classification
system, which stages cancers according to the tumour size and
depth of invasion (T), the presence and extent of regional lymph
node metastases (N), and the presence of distant metastases (M).4
The individual TNM categories can be grouped into stages I–IV
reflecting improved survival for patients with early- compared to
advanced-stage tumours.4 Nevertheless, tumours of the same
stage are heterogeneous with respect to aggressiveness and
response to therapy. Thus, the TNM classification needs reinforce-
ment with biomarkers that more reliably reflect the biological
diversity of these tumours to better tailor the treatment to the
patient’s need.
The promising results of immuno-modulating therapies such as
PD-1/PD-L1-blocking antibodies demonstrate that the immune
system is significantly involved in tumour progression,5,6 and have
boosted the interest in tumour immunology. However, the
immune system is complex, and infiltrating immune cells may
exert various roles in different types of cancer as well as within
different sub-locations of a single tumour.7–9 Although a plethora
of immune-biomarkers have been launched as useful prognos-
ticators for OSCC patients,10–12 none of them have been generally
accepted and implemented in clinical practice. Major concerns
have been raised about the poor quality of many biomarker
studies.10,13 The US National Cancer Institute and the European
Organization for Research and Treatment of Cancer initiated the
development of the REporting recommendations for tumour
MARKer prognostic studies (REMARK) guidelines, which were in
2005 simultaneously published in five cancer-related international
journals.14 These guidelines are a 20-item checklist outlining the
minimum information and analyses needed in prognostic marker
studies to ensure quality, reproducibility and opportunity to pool
studies in meta-analyses.
Recognising the involvement of the immune system in cancer
and the need for reliable prognostic markers for OSCC, we have
conducted a systematic review and meta-analysis of studies
assessing the prognostic value of tissue-infiltrating immune cells
in OSCC by survival analysis. We have included studies employing
immunohistochemistry to detect one or several of the following
immune cells: T cells, B cells, macrophages, dendritic cells (DC),
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mast cells and natural killer (NK) cells. We have also assessed to
what extent the clinical and pathological data, immunohisto-
chemical staining and scoring procedures as well as results were
adequately described in the reviewed papers, according to the
REMARK guidelines.14 Proper reporting of these parameters allows
the reader to evaluate the quality and reliability of the results, and




Included in the review were original articles that fulfilled all the
following criteria, as further elaborated in the text below:
● were written in English,
● presented data from patients with SCC in the oral cavity
proper,
● analysed tissue that had not been previously exposed to
radiotherapy and/or chemotherapy,
● used immunohistochemistry on tumour tissue sections to
recognise the immune cells of interest,
● addressed the prognostic value of tumour-associated macro-
phages, DC, NK cells, mast cells, T cells and/or B cells by
univariate and/or multivariate survival analyses of at least 40
OSCC patients, and
● employed some kind of survival as endpoint in the survival
analyses
Cancers from different sites of the head and neck region, such
as the oral cavity, the oropharynx and larynx have distinct subsite
characteristics,15 and should therefore be treated as different
entities. Thus, we only included studies that reported specific
survival data for at least 40 patients with SCC in the oral cavity
proper. Notably, the cut-off for the number of patients is based on
what we think is a reasonable cohort size to include in biomarker
studies and does not derive from the statistical analysis. Survival
endpoints with unclear or missing information were included and
interpreted as overall survival.
Sources of information, search terms and screening
We searched Embase and Medline on the 14th of March 2018
using the Ovid interface with the search terms given in
Supplementary Figure 1. If applicable, our entry terms were
defined based on Medical Subject Headings (MeSH) from
Pubmed16 to develop a controlled vocabulary. In addition to
MeSH terms, we included relevant free-text entry terms. We
defined three sets of entry terms describing (1) prognostic value,
(2) selected immune cells and (3) oral cancer. The search terms
within each set were combined with the Boolean operator OR, and
the three sets were then combined with the Boolean operator
AND. In addition, we searched the Cochrane Library and the
reference lists of reviews on related topics5,17–21 to look for
additional relevant papers. We automatically discarded duplicate
articles, non-English literature and non-human studies in Medline
and Embase. The two review authors independently extracted
relevant articles based on title and abstract. The full-text papers
were screened for all papers that appeared to meet the inclusion
criteria or in case of uncertainty. In case of uncertainty or
discrepancy, we reached consensus by analysis together. We
designed a flow diagram with the excluded cases (Fig. 1) adherent
to the Preferred Reporting Items for Systematic Review and Meta-
Analysis (PRISMA) guidelines.22
Data collection
For all studies included, we retrieved the following information
when available: name of the first author, year of publication,
number of patients, the tumour sizes or stages included, the
country and period in which the patient cohort was gathered, the
tumour compartment analysed, the primary antibody used and
survival data. If the papers reported survival data over time, e.g. by
Kaplan–Meier curves, we recorded whether tumour infiltration of
the various immune cells was associated with longer or shorter
survival, independent of the statistical significance of the
presented results. We retrieved the following statistical data when
available: statistical results from univariate and multivariate
analysis including the estimated hazard ratio (HR) or risk ratio
(RR), the associated 95% confidence interval (CI) and the P-value.
Meta-analysis
We used a random-effect meta-analysis of overall survival to
estimate the summary HR and the associated 95% CI for immune
cell markers that had been reported in at least two studies with
necessary statistical data (either univariate or multivariate
estimates of HR, and the associated 95% CI). The meta-analysis
was based on multivariate estimates of HR, as this was the most
commonly reported variable, except in the study by Ahn et al.23
where only the univariate estimate of HR was available. The
direction of HR was high vs low for all immune cells analysed. If
the HR estimate was reported in the opposite direction, we
inverted the HR and CI. We quantified the heterogeneity of HRs
across studies using I² statistics.24 Robustness of the statistical
outcome of at least three studies was evaluated by assessing the
effect of deleting each study in turn.25 The data presented in Fig. 2
were pooled using the generic inverse variance approach and the
random effects model. Analyses were performed and forest plots
created using Review Manager (RevMan) V.5.3.26
Assessment of reporting quality
We assessed the reporting quality of the studies eligible for meta-
analysis according to the REMARK guidelines.14 Of the original 20-
item checklist, we chose three broad categories that we deemed
pertinent for our review. Each study was judged based on the
following broad categories: the study cohort, the immunohisto-
chemical staining and scoring as well as the analysis and
presentation of the results. The parameters evaluated for each
of these categories were as follows: Study cohort: number of
patients, tumour stage/size and chemotherapy /radiation expo-
sure of tissue prior to surgery; Immunohistochemical staining:
antibody clone/product number, immunohistochemistry proce-
dures, positive and negative controls; scoring: number of
observers, clear scoring criteria, inter/intra-observer variability;
Analysis and presentation of the results: analysed survival
endpoint, direction of effect on survival in Kaplan–Meier plot,
estimated effects with CI for the marker, and at least for the final
model, all other variables in the model.
RESULTS
We identified 1960 records in our search, of which 33 articles were
eligible for this systematic review (Fig. 1). We conducted meta-
analysis on overall survival for CD68, CD163, CD57 and CD8, as at
least two studies provided the necessary statistical data (HR and
associated 95% CI) for these biomarkers. The pooled estimates
were calculated from two studies each for CD68 and CD57, and
from three studies each for CD163 and CD8. The results of the
systematic review are summarised in Tables 1–3, and the results of
the meta-analysis are summarised in Fig. 2.
CD163+macrophages and CD57+ NK cells have prognostic
potential
Macrophages were the most commonly studied cells of those
addressed in this review27–41 (Table 1), and the majority of the
studies reported a negative effect on survival of this cell type. A
few studies scored macrophages infiltrating the tumour islands
and the tumour–stroma separately and found that the effect on
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survival differed between the compartments. However, there was
no consistency in subsite-specific effect of macrophage infiltration
between the studies (Table 1). Meta-analysis of eligible studies
showed a significant adverse effect of a high number of CD163+
M2 macrophages42 on overall survival (P < 0.0001) (Fig. 2a).
Eliminating one study in turn did not alter this result, providing
rather strong evidence for the robustness of this meta-analysis. On
the contrary, cells detected by the pan-macrophage marker CD68
did not show significant association with overall survival in the
meta-analysis (P= 0.22) (Fig. 2b).
Three studies assessed the prognostic value of activated NK
cells using CD57 as a marker29,43,44 (Table 2), of which two were
eligible for meta-analysis. In the meta-analysis, a high number of
these cells were associated with a statistically significant survival
benefit (P < 0.0001) (Fig. 2c). We found no evidence of between-
study heterogeneity for neither CD57 nor for CD163. The single
study that used the pan NK cell marker CD56 found no effect on
survival45 (Table 2).
T cells, B cells, DC and mast cells lack evidence of prognostic
usefulness
Thirteen different studies assessed various subsets of
T cells23,28,29,34,40,44–51 (Table 3). High numbers of tumour-
infiltrating CD3+ T cells (pan T cell marker), CD4+ T cells (T helper
(Th) cell marker) or CD8+ T cells (T cytotoxic (Tcyt) marker) were
usually associated with somewhat longer survival, whereas high
numbers of forkhead box P3 (FOXP3)+ T-regulatory cells showed
significant association with decreased survival in two of the five
studies addressing this cell type. Three CD8 studies were eligible
for meta-analysis, which did not support a prognostic value for
this cell type (P= 0.17) (Fig. 2d). There was evidence of between-
study heterogeneity in the effect of CD8 (I2= 76%, P= 0.02). We
could not perform meta-analysis for the other T cell types due to
lack of data.
B cells were analysed in five studies using four different
markers23,28,34,49,52 (Table 3). B cells recognised by the pan B-cell
markers CD19 and CD20 were mostly associated with survival
benefits, although statistically significant in only two of the four
studies. The single study assessing plasma cells neither reported
the direction of effect on survival nor were the results statistically
significant. B-regulatory cells were significantly associated with
decreased survival in a single study but were not independent
markers.
Seven different articles assessed the prognostic value of DC,
using seven different markers28,45,53–57 (Table 2). High numbers of
both immature CD209+ DC and plasmacytoid CD123+ DC were
associated with decreased survival in one study, whereas high
numbers of the other subsets of DC were mostly associated with
improved survival. However, the results often lacked statistical
significance. Studies that included tumour subsite-specific survival
analyses of DC infiltration showed contradictory results (Table 2).
Two studies on mast cells58,59 passed our inclusion criteria.
Both used mast cell tryptase as the cell marker, but the results
were contradicting (Table 2). We could not perform meta-analysis













Records excluded based on
irrelevance of the titles and/or
abstracts
n = 1862  
Full-text articles
assessed for eligibility
n = 98 
Full-text articles excluded
n = 65
(studies on head and neck SCC
without separate analyses of OSCC,
n ≥ 29,
studies without assessment of
relevant cells by
immunohistochemistry and/or
survival analyses, n ≥ 26
studies with less than 40 OSCC
patients in survival analyses, n ≥ 5
studies on tumours other than head
and neck SCC, n ≥ 2
studies with tissue exposed to
radio/chemotherapy prior to surgery,
n ≥ 1
studies without survival as endpoint
in analyses, n ≥ 1
animal studies, n ≥ 1)   
Studies included in
qualitative analysis
n = 33 
Duplicates excluded
n = 380 
Studies included in
quantitative analysis
n = 8 
Fig. 1 Flow chart demonstrating reasons for exclusion of studies identified in the searches
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The reporting in the studies was often incomplete
We evaluated the reporting of the study cohort, the immunohis-
tochemical staining and scoring procedures, as well as the analysis
and presentation of the results for the studies included in the
meta-analysis, based on a checklist adapted from the REMARK
guidelines14 (Fig. 3). None of the studies completely adhered to
our checklist, and there was a huge variation in the amount of
information given and how it was presented. In general, the
included studies scored higher in the categories “study cohort”
and “analysis and presentation of the results” compared to
“immunohistochemical staining and scoring”, where all studies
lacked information about at least one parameter in the
subcategory “scoring”. The information that was most often
missing was the inter- and/or intra-observer variability for the
different scorings, and the use of positive and negative controls
for immunohistochemical staining. Other weaknesses included a
lack of reporting of medical treatment prior to surgery and a lack
of illustration of direction of survival in Kaplan–Meier plots. These
weaknesses induce a risk of comparing groups with different
baseline characteristics (selection bias), that received different care
(performance bias), and where the results were interpreted in
systematically different ways (detection bias). Contrary, we found
no strong indication of reporting/publication bias, as many studies
reported results that were not statistically significant (Tables 1–3).
DISCUSSION
OSCC are highly immunogenic tumours5,60 that are often
characterised by abundant infiltration of immune cells. In this
study, we have reviewed the current literature on the prognostic
potential of tumour-infiltrating macrophages, DC, mast cells and
lymphocytes in OSCC. We have also performed meta-analysis of
studies that provided the necessary statistical data and have
assessed the completeness of reporting of the study cohort, the
immunohistochemical staining and scoring as well as the analysis
and presentation of the results in these studies. CD163+M2
macrophages and CD57+ NK cells were the only biomarkers that
were statistically significant in pooled meta-analysis on overall
survival and seem to have the best prognostic potential of the
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Heterogeneity: Tau2 = 0.00; Chi2 = 0.40, df = 2 (P = 0.82); l2 = 0%
Test for overall effect: Z = 4.16 (P < 0.0001)
Heterogeneity: Tau2 = 0.00; Chi2 = 0.42, df = 1 (P = 0.52); l2 = 0%
Test for overall effect: Z = 1.23 (P = 0.22)
Heterogeneity: Tau2 = 0.07; Chi2 = 1.19, df = 1 (P = 0.28); l2 = 16%
Test for overall effect: Z = 4.93 (P < 0.00001)
Heterogeneity: Tau2 = 0.15; Chi2 = 8.20, df = 2 (P = 0.02); l2 = 76%
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Fig. 2 Forest plots illustrating the results of meta-analysis of studies assessing the prognostic value of a CD163-positive, b CD68-positive,
c CD57-positive and d CD8-positive tissue-infiltrating immune cells in oral squamous cell carcinoma
Tissue-infiltrating immune cells as prognostic markers in oral squamous. . .







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Tissue-infiltrating immune cells as prognostic markers in oral squamous. . .
E Hadler-Olsen and AM Wirsing
718
A high count of tumour-infiltrating CD163+M2 macrophages
was significantly associated with decreased overall survival in
pooled meta-analysis (Fig. 2a). Macrophages are phagocytic and
antigen-presenting cells of the innate immune system, and are
often among the most abundant immune cells in the tumour
microenvironment.61 Macrophages can differentiate into several
phenotypes depending on environmental cues. Classically acti-
vated or M1 macrophages can be induced by factors such as
lipopolysaccharides, interferon gamma (INFɣ) and tumour necrosis
factor (TNF). These cells can produce pro-inflammatory cytokines,
stimulate a Th1 immune response and are thought to be tumour-
suppressive. Alternatively activated or M2 macrophages can be
induced by interleukin (IL) 4, -10 and -13, as well as by
corticosteroids and prostaglandin E. These cells are involved in
tissue repair, angiogenesis and immunosuppression, and can
promote tumour growth.61,62 However, recent evidence suggests
that there is a continuum of phenotypes between the “pure” M1
and M2 macrophages, and that the cells may be redirected from
one phenotype towards the other.63 Tumour-associated macro-
phages are often differentiated towards the tumour-supporting
M2 phenotype, which is also reflected by our results where high
counts of CD68+ and CD163+ cells were mostly associated with
decreased survival. However, only CD163 was statistically sig-
nificant in pooled meta-analysis, indicating that CD163 is a more
reliable prognostic marker in OSCC than CD68. This might indicate
that there is a mixture of macrophage subtypes in the tumour,
where some of those recognised by the pan-macrophage marker
CD68 may have tumour-suppressive activities. Furthermore, cell
types other than macrophages, such as subtypes of lymphocytes,
may also express CD68.64 This may further weaken the prognostic
strength of this marker.
In contrast to CD163, a high count of tumour-infiltrating CD57+
NK cells was significantly associated with improved overall survival
in pooled meta-analysis (Fig. 2c). NK cells are important effector
cells of the innate immune system. They share many common
features with Tcyt cells, but in in contrast to Tcyt cells, they can kill
cells lacking the self-recognition marker major histocompatibility
complex 1 without further activation.65 NK cells also produce
cytokines such as INFɣ that activate other immune cells, including
M1 macrophages.11,66 This supports the NK cells’ role as potent
tumour suppressors and putative prognostic markers. As for most
other immune cells, there are several subtypes of NK cells, where
the two main populations are the CD56bright and the CD56dim.
CD56dim NK cells have a higher expression of proteins such as
perforin and granzymes than CD56bright and are therefore more
cytotoxic. In contrast, the CD56bright NK cells produce higher
amounts of INFɣ, and have more potent immune regulatory
functions.67 Based on the available data, CD57+was the only
significant biomarker for NK cells. Only CD56dim NK cells express
CD57,67,68 thus this marker may more precisely detect NK cells
with high cytotoxic activity. The only study that assessed the
prognostic value of NK cells recognised by the pan NK cell marker
CD56 found no statistically significant survival effect of these cells.
Notably, all studies on CD163 and CD57 included in the meta-
analysis were performed on an East-Asian patient cohort (Tables 1
and 2), and ethnical and cultural differences along with varying
access to health care and diverse treatment regimens call for care
when extrapolating results based on patients from one part of the
world to others. Thus, well-controlled studies are needed to
confirm the robustness and relevance of CD163+ and CD57+ cells
as prognostic markers in OSCC patient cohorts outside of Asia.
The other cell types addressed in this review lack evidence of
prognostic usefulness. Most of these immune cells can be divided
into a number of different subclasses with distinct functional
properties. This was most notable for DC analysed with seven
different markers (Table 2) in the seven articles on DC eligible for
this review. DC are potent antigen-presenting cells and important
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Table 2. Studies assessing the prognostic value of dendritic cells, mast cells and natural killer cells in OSCC
Authors, ref. Number of patients, tumour size/










Marker: CD1a, monocyte-derived DC and Langerhans cells
Jardim et al.56 53, Stage I–IV, 2002–2010, Brazil Intratumour Positive OS: P= 0.148 NA
DFS: P= 0.089 NA
Peritumour Positive OS: P= 0.03 OS: P= 0.001, HR 0.277
(95% CI 0.126–0.613)b
DFS: P= 0.007 DFS: P= 0.001, HR 0.236
(95% CI 0.109–0.510)b
Sakakura et al.45 74, Stage I–IV, 2000–2012, Japan Tumour periphery No info OS: P= 1.000 NA
PFS: P= 1.000 NA
Goldman et al.55 43, T1–T4, 1987–1998, US Peritumour Positive DSS: P= 0.05 DSS: P= 0.23
Intratumour Negative DSS: P= 0.21 DSS: P= 0.04
Marker: S100, pan DC marker
Reichert et al.54 132, Stage I–IV, 1980–1993, Germany Stroma Positive OS: P < 0.001 OS: P ≤ 0.001, HR 0.422
(CI no info)
Goldman et al.55 43, T1–T4, 1987–1998, US Peritumour Positive DSS: P= 0.30 DSS: P= 0.07
Intratumour Negative DSS: P= 0.24 DSS: P= 0.80
Marker: CD83, mature DC
Jardim et al.56 53, Stage I–IV, 2002–2010, Brazil Intratumour Positive OS: P= 0.274 NA
DFS: P= 0.346 NA
Peritumour Positive OS: P= 0.276 NA
DFS: P= 0.392 NA
Marker: P55, fascin-expressing DC
Reichert et al.54 129, Stage I–IV, 1980–1993, Germany Stroma Positive OS: P < 0.001 OS: P > 0.05
Marker: CD208/DClamp, mature DC
Wirsing et al.28 69, T1–T4, 1986–2002, Norway Stroma Positive DSS: P= 0.639 NA
Ni et al.53 79, Stage I–IV, 2011–2012, China Nest Positive OS: P > 0.05 NA
Stroma Negative OS: P > 0.05 NA
Marker: CD123, plasmacytoid DC, pre-DC
O’Donnel et al.57 63a, T1–T4, Period missing, US Extranestal Negative/no info OS: P < 0.0001, NA
Intratumour Negative/no info. Compartment unclear NA
Marker: CD209/DCsign, immature DC
O’Donnel et al.57 63a, T1–T4, Period missing, US Extranestal Negative/ no info OS: P < 0.0001, NA
Intratumour Negative/no info. Compartment unclear NA
Mast cells
Marker: mast cell tryptase
Akbarzadeh
Baghban et al.43
57a, Stage missing, Period missing,
Iran
Peritumour No info NA OS: P= 0.719, HR 1.117
(95% CI 0.612–2.039)
Ishikawa et al.59 81a, Stage I–IV, 1982–2007, Japan Stroma Negative DFS: P= 0.038 NA
Natural killer cells
Marker: CD56, pan NK cell marker
Sakakura et al.45 74, Stage I–IV, 2000–2012, Japan Tumour periphery No info OS: P= 1.000 PFS:
P= 1.000
NA
Marker: CD57, mature/activated NK cell marker
Fang et al.29 78a, Stage I–IV, 2007–2009, China Stroma Positive OS: P < 0.001, HR 0.130
(95% CI 0.061–0.274)b
OS: P < 0.001, HR 0.152
(95% CI 0.064–0.361)b
Taghavi et al.43 57a, Stage missing, Period missing,
Iran
Intratumour Positive NA OS: P < 0.001, HR 0.058
(95% CI 0.013–0.262)b
Zancope et al.44 40, Stage I–IV, Period missing, Brazil Peritumour No info OS: P= 0.70 NA
Intratumour No info OS: P= 0.69
OS overall survival, if survival was not specified it was interpreted as overall survival, DSS disease-specific survival, PFS progression-free survival, DFS disease-
free survival, HR hazards ratio, NA Not applied
Significant values are bold (p< 0.05)
aDenotes that information about chemotherapy/radiation exposure of tissue prior to surgery was missing or ambiguous
bDenotes that the HR and CI were inverted in these studies
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Plasmacytoid DC are derived from lymphoid progenitor cells and
have an important role in the fight against viral infections. CD123
is often used as a marker for plasmacytoid DC, but the protein is
also expressed by pre-DC that can differentiate into other DC
subtypes.69 In addition, there are two main classes of conventional
(c) DC derived from myeloid progenitor cells, cDC1 and cDC2.
cDC1 cells express high levels of CD141 and low levels of CD11b
and CD11c.70 They are potent activators of CD8+ Tcyt cells and
promote a Th1 response. Compared to cDC1 cells, cDC2 cells are
less abundant, and express high levels of markers such as CD1c,
CD11b and CD11c. Several subsets of cDC2 cells exist that can
elicit a wide range of responses, including both Th1 and Th2
activation.69 In addition to DC originating from lymphoid and
myeloid progenitor cells, DC can also derive from monocytes
under inflammatory conditions.71 Monocyte-derived DC express
high levels of CD11c and CD1a. CD1a is however also expressed by
Langerhans cells, specialised DC found in the basal layer of
stratified squamous epithelium. Functionally, Langerhans cells
seem to have much in common with cDC1 cells.72 Different
activation/maturation statuses can further influence the functional
properties of the various DC subtypes.69 To determine DC subtype
and activation status, requires detection of several markers
simultaneously by double-, triple or even quadruple immunohis-
tochemical staining. This is technically demanding, and none of
the DC studies reviewed used more than one marker at a time.
Furthermore, cell types other than DC can be positive for the
markers used, such as S100 that is expressed by a broad range of
cell types. Thus, based on our results from the reviewed literature,
it is impossible to draw reliable conclusions about the prognostic
potential of the various DC subtypes. The diversity of DC makes
precise immunohistochemical identification of DC subtypes
complicated and questions the feasibility of using DC immuno-
histochemical detection for prognostic purposes.
Mast cells are of hematopoietic origin, and are loaded with
granules containing bioactive molecules such as growth factors,
interleukins, chemokines and proteases, of which mast cell
tryptase is often used as a mast cell marker.73 Upon activation
through stimuli such as immune receptors, pathogens or
endogenous compounds, mast cells can release these molecules
and initiate a wide range of immune responses.74 Mast cells are
linked to immunoglobulin E-mediated immune responses, but are
increasingly recognised to serve multiple tissue functions includ-
ing regulation of blood flow, wound healing as well as innate and
adaptive immune responses.75 Through crosstalk with B cells,
T cells and DC, mast cells may have important regulatory
functions.74 In human solid tumours, mast cells are believed to
have dual effects. Secretion of IL-8 and vascular endothelial
growth factor can promote angiogenesis and tumour growth,
Authors, year Study cohort
Immunohistochemical Analysis and
presentation
of the resultsStaining Scoring
Ahn et al, 2017
Fang et al, 2017
Wu et al, 2017
Taghavi et al, 2016
Matsuoka et al, 2015
Ni et al, 2015
Wang et al, 2014
Fuji et al, 2012
All parameters given
Lacks/unclear information about one of the parameters
Lacks/unclear information about more than one of the parameters
Fig. 3 Assessment of the reporting quality of the studies included in the meta-analysis. The reporting of the following parameters was
evaluated: Study cohort, (1) number of patients, (2) tumour size/stage, (3) chemotherapy/radiation of tissue prior to surgery;
Immunohistochemical staining, (1) antibody clone/product number, (2) immunohistochemistry procedures, (3) positive and negative
controls; scoring (1) number of observers, (2) clear scoring criteria, (3) inter/intra-observer variability; Analysis and presentation of the results,
(1) survival endpoint analysed, (2) direction of effect on survival in Kaplan–Meier plot, (3) estimated effects with confidence intervals for the
marker and, at least for the final model, all other variables in the model
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whereas release of cytotoxic cytokines and TNFα may have
tumour-suppressive effects.76 Neither of the two studies addres-
sing mast cells in our review found them to be independent
predictors of patient survival. However, as for many other immune
cells, it could be that the full spectrum of mast cell diversity is yet
to be elucidated. Data on the function and prognostic value of
mast cells in human tumours are sparse, and more studies are
warranted.
T cells and B cells are the main cells of the adaptive immune
response. T cells, recognised by the pan T cell marker CD3, are
broadly divided into CD4+ T helper (Th) cells and CD8+ Tcyt
cells.77 The CD4+ Th cells produce an array of cytokines that
modulate neighbouring immune cell function, and release
chemokines that attract inflammatory cells. Dependent on the
stimuli, CD4+ Th cells can differentiate into a number of subsets
including Th1, Th2, Th9, Th17 and Treg cells, which each release
specific cytokines and chemokines and thereby have distinct
functions. The Th1 response is triggered by cytokines such as INF
α/β and IL-12, and is characterised by release of large amounts of
INFɣ and TNFα.78 This in turn may stimulate generation of M1
macrophages and suppress tumour growth.61 Th2 cells are
differentiated in response to IL-4, whereupon the Th2 cells
produce vast amounts of IL-4, -5 and 13. These cytokines can
stimulate basophils, mast cells and eosinophils, as well as promote
differentiation of tumour-promoting M2 macrophages.79 TGFβ can
promote differentiation of Treg cells, often recognised by
expression of the transcription factor FOXP3. Treg cells also
produce TGFβ as well as IL-12, which inhibit T cell proliferation and
cytokine release, thereby dampening the immune response.80 This
could represent a mechanism of conveying immune surveillance
of a tumour, yet, the studies included in this review show
contradicting result on the prognostic value of FOXP3+ cells. As
for the DC, a panel of antibodies would be needed to accurately
identify the presence and localisation of the numerous CD4+ T
cell subtypes. Merely staining with CD3 or CD4 recognises cells
with a broad range of functions and may therefore have limited
prognostic usefulness.
For CD8+ T cells, fewer functional subtypes have been
recognised than for CD4+ T cells. Similar to Th1 cells, CD8+ Tcyt
cells are stimulated by IL-12 and INFα/β. Upon stimulation, they
produce INFɣ and TNFα in addition to granzymes and perforin,
which can lyse and kill neighbouring cells.81 Thus, Tcyt cells may
efficiently kill tumour cells, and have important tumour suppressor
functions. However, signalling through receptors such as CTLA-4
and PD-1 on Tcyt cells may inhibit their cytotoxic activity.82
This could explain why we did not find any statistically
significant association between CD8+ cells and survival in the
meta-analysis.
B cells are another major player in the adaptive immune
response, more specifically in the humoral response. B cells are
often recognised by the pan markers CD19 or CD20.83 Upon
binding of an antigen compatible with their specific receptor, and
supported by cytokines released from Th cells, B cells can
differentiate to plasma cells and produce antibodies specific to
the antigen that triggered their differentiation.84 However, B cells
also act as antigen-presenting cells, promote differentiation of
Th1 cells and Tcyt cells, and directly kill cancer cells through
release of Granzyme B.85 These functions support a tumour-
suppressive role for B cells. However, as for T cells, immune-
suppressive subtypes of B cells have been detected, termed B-
regulatory (Breg) cells. Similar to Treg cells, these cells produce
TGFβ and IL-10, promoting the same down-stream effects as
described for Treg cells.83 This heterogeneity in B-cell function
may explain the lack of consensus in results on cells using pan B-
cell markers. The single study exploring Breg cells showed a
negative but not independent effect on survival. B-cell maturation
and activation normally happens in secondary lymphoid organs
but may also take place in tertiary lymphoid structures that are
aggregates of lymphocytes organised as lymphoid follicles at sites
of inflammation. Such structures have been found in several types
of cancer including OSCC,86 where they may act as sites of T cell
and B-cell activation and antibody production in the tumour
microenvironment. This suggests that the function of immune
cells may depend on how these cells are organised in the tumour
microenvironment.73–76
The anatomical location of the tumour within the oral cavity
may also influence the prognostic value of immune cells. Most of
the studies in this review included patients with cancers at various
intraoral locations, but hardly any of them reported subsite-
specific prognostic data. More often, various tumour compart-
ments were analysed for immune cell infiltration, e.g. the invasive
front, the tumour periphery or the tumour nests (Tables 1–3).
However, the definition of these compartments was often unclear,
making it difficult to compare the results. Furthermore, some
studies used resection samples whereas others used tissue
microarrays or biopsy samples, where the latter may be less
representative of the whole tumour.
The reliability of our results is limited by reporting deficiencies
in the included studies, which we assessed based on a checklist
adapted from the REMARK guidelines. All studies included in our
meta-analysis were published at least 7 years after the REMARK
guidelines were first introduced in 2005, and most of them were
conducted after an elaboration of the REMARK guidelines was
published in 2012.87 None of the studies included in this review
provided all of the recommended information (Fig. 3), and the
reporting of immunohistochemical staining and scoring protocols
was insufficient in most of the studies. This, along with results
from a recent study88 indicate that the use of the REMARK
guidelines is yet to be implemented in research practice. In 2018,
an abridged explanation and elaboration of the REMARK guide-
lines was published to encourage dissemination of the REMARK
checklist,89 and it will be interesting to see if adherence of the
REMARK guidelines improves in the scientific community. Proper
reporting of the study cohort and—design, assay methods,
statistical analyses and results allows transparency and reliability
of prognostic marker studies.
Several of the reviewed papers merely stated whether a marker
was statistically significant or not based on a P-value and
significance level but did not report the P-value itself or the
direction of the effect on survival. However, small differences in
study design such as the inclusion or exclusion of patients can
shift the P-value above or below the common 0.05 level of
significance.90 Especially in small studies and when controlling for
multiple parameters, the prognostic value of a marker is likely to
be underestimated. Thus, evaluating the effect size and direction
on survival may be a more suitable approach to estimate the
prognostic value of a marker.90 When extracting data for this
systematic review, we tried to interpret whether infiltration of the
various cell types was associated with longer or shorter survival,
independent of the statistical significance of the association, as
indicated in Tables 1–3. Importantly, the effect on survival in many
of the studies was minor, and conclusions derived from these
studies may have poor reliability. Only a small number of studies
reported the necessary statistical data to be eligible for meta-
analysis, which limits the reliability of our conclusions. More
rigorous reporting of statistical data will help to increase the
quality of individual studies and opens the possibility to
summarise the existing data in meta-analyses.
CONCLUSION
Important clinical information or reporting of immunohisto-
chemical staining and scoring protocols as well as statistical data
were often missing in the papers reviewed in this study. Thus,
there is a need for journal editors and reviewers to focus more
on the quality of data reporting in prognostic marker studies to
Tissue-infiltrating immune cells as prognostic markers in oral squamous. . .
E Hadler-Olsen and AM Wirsing
724
increase their impact and usefulness. With these methodological
limitations in mind, we conclude that M2 macrophages
identified by CD163 and mature NK cells identified by
CD57 seem to be the most promising prognostic factors of the
immune cells analysed in this review. However, the prognostic
value of CD163+M2 macrophages and CD57+ NK cells should
be confirmed in a large cohort of OSCC patients with
transparent and comprehensive reporting of study design and
conduct. All other evaluated cells show conflicting or statistically
insignificant results, and their potential as prognostic markers is
far from being established.
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